CAJ | 학술논문

目的：观察分析多西紫杉醇联合替吉奥在治疗蒽环类耐药三阴性乳腺癌（triple-negtive breast cancer，TNBC）中的临床疗效。方法选择2009年6月～2011年6月绍兴市人民医院肿瘤放疗科收治的64例三阴性乳腺癌患者，回顾性分析上述病例的临床资料，所有患者使用蒽环类药物治疗无效或复发，继而选择联合多西紫杉醇、替吉奥治疗，观察分析此种方案的临床疗效和不良反应情况。结果64例患者的治疗后有效率为54.69％，病情控制率为79.69％，治疗过程中未见死亡病例，主要不良反应为胃肠道反应和骨髓抑制，但患者对此均可耐受；随访结果显示中位疾病进展时间为10.5个月，2年后无疾病进展生存率为0。结论联合多西紫杉醇、替吉奥治疗蒽环类耐药三阴性乳腺癌的临床效果良好，不良反应相对较轻，是较为理想的辅助化疗方案。
목적：관찰분석다서자삼순연합체길오재치료은배류내약삼음성유선암（triple-negtive breast cancer，TNBC）중적림상료효。방법선택2009년6월～2011년6월소흥시인민의원종류방료과수치적64례삼음성유선암환자，회고성분석상술병례적림상자료，소유환자사용은배류약물치료무효혹복발，계이선택연합다서자삼순、체길오치료，관찰분석차충방안적림상료효화불량반응정황。결과64례환자적치료후유효솔위54.69％，병정공제솔위79.69％，치료과정중미견사망병례，주요불량반응위위장도반응화골수억제，단환자대차균가내수；수방결과현시중위질병진전시간위10.5개월，2년후무질병진전생존솔위0。결론연합다서자삼순、체길오치료은배류내약삼음성유선암적림상효과량호，불량반응상대교경，시교위이상적보조화료방안。
Objective To observe and analyze the clinical efficacy of docetaxel and S-1 in treatment of anthracycline-resistant triple-negtive breast cancer(TNBC).Methods 64 cases with TNBC admitted in People' Hospital of Shaoxing City from June 2009 to June 2011were selected as research object.The clinical data of these cases were analyzed retrospectively.Anthracycline had been used to treat the cases, but with no effect or recurrence.Then docetaxel combined with S-1 was applied to the cases.Clinical efficacy and adverse reactions of the chemotherapy were observed and analyzed. Results After treatment,the efficiency of 64 cases was 54.69%,and the disease control rate was 79.69%.During the treatment,the main adverse reactions were gastrointestinal reactions and bone marrow suppression,without death,and patients could tolerate the adverse event.Follow-up results showed that the median time of progression was 10.5 months.After two years,progression-free survival rate was 0.Conclusion Docetaxel combined with S-1 has good clinical efficacy for anthracycline-resistant triple-negtive breast cancer,with relatively mild side effects,which may be an ideal adjuvant chemotherapy method.